"Authors","Title","Journal","Year","study_design","aims","intervention1","intervention2","intervention3","description","inclusion_criterion1","inclusion_criterion2","inclusion_criterion3","inclusion_criterion4","inclusion_criterion5","inclusion_criterion6","inclusion_criterion7","inclusion_criterion8","exclusion_criterion1","exclusion_criterion2","exclusion_criterion3","exclusion_criterion4","exclusion_criterion5","exclusion_criterion6","exclusion_criterion7","exclusion_criterion8","exclusion_criterion9","exclusion_criterion10","exclusion_criterion11","exclusion_criterion12","exclusion_criterion13","exclusion_criterion14","exclusion_criterion15","exclusion_criterion16","exclusion_criterion17","exclusion_criterion18","exclusion_criterion19","exclusion_criterion20","exclusion_criterion21","exclusion_criterion22","exclusion_criterion23","exclusion_criterion24","exclusion_criterion25","exclusion_criterion26"
"Altman et al. 2011","Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study.","Mov. Disord.","2011","Quasi-experimental study","To establish the optimal tolerated caffeine dose in iPS-patients and to assess potential motor and nonmotor benefits in a pilot study","adenosine_antagonists",NA,NA,"Start with 200mg caffeine qd and increase of 200mg per week until dosage of 1000mg qd; assessment of effect after six weeks","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"consumption of caffeine of more than 200 mg daily calculated from standardized nutrition charts"," dementia with Mini Mental State Examination of less than 26 and activities of daily living impairment secondary to cognitive loss"," active peptic ulcer disease"," severe intolerance or allergy to caffeine"," recent changes to antiparkinsonian medication during four weeks before entering the trial"," supraventricular cardiac arrhythmia"," uncontrolled hypertension"," current use of prescribed alerting agents"," intake of lithium or clozapine"," premenopausal women not using effective methods of birth control.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Anderson et al. 1992","Trial of Sinemet CR4 in patients with Parkinson's disease",NA,"1992","Quasi-experimental study","Assess the safety and tolerability of Sinemet CR4 for parkinsonian symptoms","levodopa",NA,NA,"After four months of medication optimisation, levodopa gradually replaced by sinemet with continuous relase formulation during 12 weeks. After this baseline period the study began and results were ascertained after 52 weeks","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Arnold et al. 2005","High doses of pergolide improve clinical global impression in advanced Parkinson's disease - A preliminary open label study","Arch Gerontol Geriatr","2005","Quasi-experimental study","Evaluate efficacy and saftey of high-dose pergolide treatment in patients with moderate to severe PD and to assess amounts of reduction in levodopa, improvement in UPDRS and adverse reactions","pergolide",NA,NA,"Patients under medication with bromocriptine, lisuride, alpha-dihydroercocryptine or ropinirole switched to equivalent starting dose pergolide, over twelve weeks pergolide dosage enhanced at 0.5mg steps until 3mg qd and 1mg steps after reaching 3mg qd; levodopa dose weekly or bi-weekly decreased in 100mg steps. Afterwards twelve weeks dosage unchanged, clinical assessment after 24 weeks.","Advanced iPS according to unknocn criteria"," previous treatment with levodopa with stable dosage over three months"," previous treament either pergolide, bromocriptine, lisuride, dihydroergocryptine, ropinirole or selegiline at stable dosage over at least one month before entering study",NA,NA,NA,NA,NA,"Concurrent or past diagnosis of malignant melanoma"," history of psychosis including schizophrenia"," severe depression"," past or current history of non-febrile seizures"," active gastric or duodenal ulcer or ulcer within past 12 months"," significant or unstable medical condition (including serious hepatic, cardiovascular, pulmonary, renal disease) or serum concentration of any enzyme greater than twice upper limit of reference","  serum creatinine concentration greater than 1.5 times upper limit"," pregnancy"," lactation or women with childbearing potential w/o medically accepted contraception",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Bara-Jimenez et al. 2003","Adenosine A2A receptor antagonist treatment of Parkinson's disease","Neurology","2003","Randomised-controlled trial (RCT)","evaluate pathogenic and therapeutic potential of adenosine A2A receptor-mediated mechanisms in iPS-patients","adenosine_antagonist",NA,NA,"Patients randomized to a. placebo and KW-6002 group as 1 to 3 ratio. b. KW6002 group received two week placebo, two weeks 40mg qd and two weeks 80mg. Three evaluations with motor functions assessed a. when KW6002 alone, b. KS6002 coadministered with suboptimal and optimal dose, steady state levodopa infusion iv, c. periodically after discontinuation of levodopa","moderate to advanced iPS according to unknown clinical criteria"," stable regimen of levodopa and short-acting dopamine agonists for at least four weeks prior to study",NA,NA,NA,NA,NA,NA,"history of bilateral intracranial surgery for iPS"," premedication with centrally acting medication other than approved antiparkinsonian drugs"," hepatotoxic drugs or drugs metabolized by CYP450_3A4"," exposure to KW_6002 before or other investigational drug within two months",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Barbagallo et al. 2018","The placebo effect on resting tremor in Parkinson's disease: an electrophysiological study","Parkinsonism Relat. Disord.","2018","Quasi-experimental study","Assess effects of placebo on resting tremor","placebo"," apomorphine",NA,"Administration of a. placebo and b. apomorphine sc., tremor assessment after 30 and 60 minutes","iPS according to diagnostic criteria as defined by Jankovic et al."," resting tremor with item 20 of UPDRS more than 2 for at least one hand during physical examination"," damage to the nigrostriatal dopaminergic system on DAT-SPECT imaging",NA,NA,NA,NA,NA,"cognitive impairment with an MMSE score of less than 24"," neurological, cerebrovascular or thyroid comorbidities"," moderate to severe dyskinesias"," normal DAT-SPECT","  evidence of brain tumor, marked atrophy, and/or diffuse white matter hyperintensities on MRI"," treatment with deep brain stimulation"," general exclusion criteria for MRI scanning. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Binder et al. 2008","Effect of Cabergoline on Parkinsonian Tremor Assessed by Long-Term-Actigraphy","European Neurology","2008","Quasi-experimental study","Study anti-tremulous effect of cabergoline; validate long-term actigraphy","cabergolin"," pergolide",NA,"baseline period of 3 days, initial dosage of 0,5mg cabergoline on day 4, titration phase of 1mg increase per week, two weeks maintenance, clinical visits after three and six weeks.","iPS according to UK Brain Bank criteria"," moderate to marked rest tremor at one arm (item 20 UPDRS larger than 2)",NA,NA,NA,NA,NA,NA,"anticholinergics, budipine or dopamine agonists in current pre-medication"," contraindications against dopamine agonists or ergotamine derivates",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Bonuccelli et al. 1997","Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration.","Neurology","1997","Randomised-controlled trial (RCT)","To evaluate the effects of acute clozapine administration on parkinsonian mixed tremor, to establish the predictive value for long-term response and to determine differences in pharmacologic response of resting and postural tremor","clozapine",NA,NA,"all antiparkinsonian medication was withdrawn twelve hours before. Administration of a 12.5mg single dose of a. clozapine or b. placebo. UPDRS at baseline and at ten minute intervals for to hours. 15 iPS-patients with more than 50 percent improvement included in chronic, open-phase study for 15.5 months.","iPS according to unknown clinical criteria"," presence of resting and postural tremor poorly responsive to levodopa",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Brannan & Yahr (1995)","Comparative Study of Selegiline Plus L-Dopa-Carbidopa Versus L-Dopa-Carbidopa Alone in the Treatment of Parkinson's Disease","Ann. Neurol.","1995","Quasi-experimental study","To evaluate the effects of selegiline as add-on to levodopa and carbidopa vs. the effect of levodopa and carbidopa alone","mao_inhibitor"," levodopa",NA,"subjects in both groups randomly matched by computer for age, years of iPS at disease onset and years of treatment. Both groups under levodopa and carbidopa therapy. Patients assessed at regular intervals and rated clinically","iPS according to unknown clinical criteria"," therapy with selegiline 5mg bid"," continued use and add-on of levodopa-carbidopa later",NA,NA,NA,NA,NA,"treatment with dopamine agonists",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Brooks et al. 1998","A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.","Clin Neuropharm","1998","Randomised-controlled trial (RCT)","To evaluate the effects and the safety of ropinirole on iPS-patients","ropinirole",NA,NA,"Randomisation to a. ropinirole or b. placebo on a 2:1 ratio. Dosage of study medication was increased at .5 steps to a maximal dosage of 5mg bid, with dosages being adjusted at the discretion of the investigator, e.g., if side effects appeared","iPS according to unknown clinical criteria"," age between 30 and 80 years"," Hoehn and Yahr stages between 1 and 4"," necessity of dopaminergic therapy",NA,NA,NA,NA,"Patients with childbearing potential"," patients with abnormalities in their medical history, physical examination or diagnostic testing that were deemed to be clinically significant"," patients with orthostatic hypotension",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Bullock et al. 2021","Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.","J Neurol Sci","2021","Quasi-experimental study","Explore effects of zuranolone on iPS-tremor as an add-on therapy","beta_blocker",NA,NA,"Treatmenr with oral zuranolone 20 or 30mg qd for 7 days","iPD defined by unknown clinical criteria"," tremor sum score MDS-UPDRS greater than 7"," tremor motor score greater than 2 on one limb in ON medication state"," stable dosage of dopaminergic medication",NA,NA,NA,NA,"Medication with amatadine or anticholinergics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Cattaneo et al. 2016","Safinamide as Add-On Therapy to Levodopa in Mid-to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE","J Parkinsons Dis","2016","Randomised-controlled trial (RCT)","To evaluate the clinical effects of safinamide on motor fluctuations and cardinal symptoms of iPS-patients","safinamide",NA,NA,"study 116: two doses of safinamide (50 and 100) used in two groups  (for post hoc analyses 100 mg included only, Study SETTLE 50 mg daily for 2 weeks, afterwards 100 mg Safinamide. For post hoc analyses treatment effects of safinamide 100 mg once daily versus placebo  during double-blind phases of Stidy 016 and SETTLE. Data of both studies were pooled. 487 received 100 mg safinamide, 484 placebo.","mid to late-stage PD"," motor fluctuations while receiving levodopa",NA,NA,NA,NA,NA,NA,"medication with another MAO-B inhibitor",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Choi et al. 2000","The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson’s disease.","J. Neurol. Sci.","2000","Quasi-experimental study","To evaluate the effects of levodopa therapy on depression in de novo patients and additionally motor scores","levodopa",NA,NA,NA,"iPS according to clinical criteria of the Core Assessment Program for Intracerebral Transplantation",NA,NA,NA,NA,NA,NA,NA,"Patients with structural lesions in the MRI"," less than 24 points in the Mini Mental State Examination",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Çinar et al. 2013","Could Apomorphine be an effective treatment option for refractory tremor in Parkinsons disease: a pilot study","Nobel Med","2013","Quasi-experimental study","To evaluate effects of apomorphine sc as an add-on for levodopa refractory tremor in iPS","apomorphine",NA,NA,"Apomorphine was administered at increasing dosages with 1, 2, 4mg every 15 minutes in OFF medication state","IPS-patients according to unknown clinical criteria"," stable dopaminergic medication"," medically refractory tremor",NA,NA,NA,NA,NA,"other significant diseases",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Craig et al. 2006","Controlled Pilot Study of the Effects of Neuromuscular Therapy in Patients with Parkinson's Disease","Mov. Disord","2006","Randomised-controlled trial (RCT)","To evaluate the effects of neuromuscular therapy on motor symptoms of iPS-patients","other",NA,NA,"Randomisation to a. group receiving NMT and b. active control group receiving music relaxation. Two 45 minutes sessions weekly for four weeks. Identical relaxation music during all sessions. Data collection at baseline, week 4 and 8 days after finishing treatment","IPS according to unknown clinical criteria"," moderately advanced disease stage"," optimal and stable medication for at least one month"," no expected medication changes within four months"," MMST greater than 20"," no major active medical or psychiatric conditions",NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Dirkx et al. 2019","Cerebral differences between dopamine-resistant and dopamine-responsive Parkinson’s tremor","BRAIN","2019","Quasi-experimental study","To ascertain increased tremor-related activity in non-dopaminergic brain regions, particularly the cerebellum in patients suffering from iPS with good response to dopaminergic therapy versus those without","levodopa",NA,NA,"Administration of  a. levodopa or placebo (200mg).","iPS-patient according to UK Brain Bank criteria"," resting tremor that is MDS-UPDRS item 17 greater than 0 at least at one limb",NA,NA,NA,NA,NA,NA,"neurologic comorbidities"," signs of psychogenic tremor"," allergies"," MMSE score less than 25"," FAB score less than 13"," improvement of less than 0,2 after levodopa in akinesia and rigidity MDS-UPDRS subscores",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Eggert et al. 2010","Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study.","J. Neural Transm.","2010","Quasi-experimental study","To investigate the efficacy, safety and feasibility of direct switch from
either levodopa and carbidopa or levodopa and benserazide to levodopa with carbidopa and entacapone in study design resembling routine
clinical practice in iPS-patients with wearing-off","levodopa"," entacapone",NA,"during baseline period of two weeks change in dosage between levodopa with decarboxlase inhibitor to lce with the possibility to adjust for dosage during this time. During six weeks period the medication had to remain unchanged","iPS-patient according to unknown clinical criteria"," age of at least 35 years"," Hoehn and Yahr stage of 1 to 3"," wearing-off, defined as more than one positive symptom in the WOQ9 questionnaire"," treatment with standard release levodopa and decarboxylase inhibitor at dosing frequency of three or four daily dosages",NA,NA,NA,"intake of COMT inhibitor six weeks prior to baseline"," concomitant treatment with non-selective MAO inhibitor"," intake of apomorphine"," concomitant medication with drugs with anti-dopaminergic action, such as reserpine, antipsychotics drugs if it did not exceed one evening dose of atypical antipsychotic drug"," medication with D2 receptor blocking antiemetics, except domperidone"," patients with unpredictable OFF periods or dyskinesia"," clinically significant concomitant diseases"," abnormal laboratory values or electrocardiogram"," females who were of childbearing potential, pregnant or lactating",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Elmer (2013)","Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials","Parkinsonism Relat. Disord.","2013","Randomised-controlled trial (RCT)","assess clinical effect of rasagiline 1mg/day on cardinal PD symptoms and motor fluctuations in defined patient subgrous using data from PRESTO and LARGO.","rasagiline",NA,NA,"Post-hoc analysis of effects of rasagiline as add-on to existing dopaminergic therapy. Data of two studies (LARGO and PRESTO) pooled with analyses of all cardinal symptoms but also subgroup analyses","iPS according to clinical criteria"," disease duration of less than 1.5 years from diagnosis"," No necessity for anti parkinsonian treatment and forseable stable situation for nine months"," willingness and ability to give informed consent",NA,NA,NA,NA,"Subjects aged less than 30 or more than 80 years"," loss of postural reflexes"," UPDRS Tremor scores of three or greater in any limb"," Hoehn and Yahr stage three or greater","  presence of freezing while walking"," subjects with history repeated strokes with stepwise progression of parkinsonian features, repeated head injury or history of definite encephalitis , sustained remission, presence of supranuclear gaze palsy, cerebellar signs, concomitant early severe autonomic involvement, presence of Babinski's sign, presence of a cerebral tumour or communicating hydrocephalus, MPTP exposure, Oculogyric crises"," subjects who have had previous use of rasagiline or selegiline, subjects trated with other anti-PD medication at any time prior to baseline"," subjects having used any other anti-PD medication (including anticholinergics) for less than three weeks prior to the three month period preceding baseline whose anti-PD medication is intentionally ceased in order for the subject to enter the study"," subjects who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete participation"," Hypertensive subjects whose BP is not well controlled according to the medical record or as observed during the week of home BP recording prior to baseline"," subjects diagnosed with melanoma based on the screening dermatologic examination, or with a history of melanoma"," subjects with suspicious lesions at baseline who do not undergo biopsy"," subjects with significant cognitive impairment as defined by MMSE score < 26"," subjects with clinically significant psychiatric illness, including major depression [Beck Depression Inventory (short form) =15"," subjects with a history of alcohol or substance abuse within the past 2 years"," subjects who have taken any experimental medications within 60 days prior to baseline"," subjects who have used coenzyme Q10 (in daily doses > 300 mg) within 120 days prior to baseline"," subjects who have used sympathomimetics (including over-the-counter remedies - nasal or oral), dextromethorphan, pethidine or St. John's Wort within the 7 days prior to baseline"," Subjects who have used antidepressants within 42 days prior to baseline"," subjects who have used ciprofloxacin, a potent CYP 1A2 inhibitor within 7 days prior to baseline"," subjects who have used MAO inhibitors including reserpine or methyldopa within the three months prior to baseline, or treatment with an anti-emetic or antipsychotic medication with central dopamine antagonist activity within the six months prior to baseline"," women who are not postmenopausal, surgically sterilized, or using adequate birth control [oral birth control pills, IUD, or a long acting injectable form of contraception"," barrier methods alone (i.e., condom) are not sufficient]. Women of childbearing potential without a negative pregnancy test at screening. Nursing women",NA,NA,NA
"Evidente et al. 2003","Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience.","Parkinsonism Relat. Disord.","2003","Quasi-experimental study","To report experiences with piribedil as adjunct therapy to levodopa in Filipino patients with advanced iPS","piribedil",NA,NA,"After baseline evaluation at week 0, start of piribedil treatment 50mg qd, slow increase of 50mg per week, evaluation after final week with UPDRS.","iPS according to Queens Square Brain Bank criteria"," age 25-85 years"," Hoehn and Yahr stadium 2.5 to 4"," motor fluctuations"," levodopa intake at least 3qd",NA,NA,NA,"Atypical parkinsonism"," pregnancy"," sexually active reproductive female patients"," history of significant cardiovascular, renal, hepatic, psychiatric disease"," signs of dementia"," history of neuroleptics intake except clozapine"," orthostatic hypotension",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Fischer et al. 1990","Treatment of parkinsonian tremor with clozapine.","J. Neural Transm.","1990","Quasi-experimental study","To assess the therapeutic efficacy of clozapine on parkinsonian tremor","clozapine",NA,NA,"previous medication with antichoinergics or beta-blockers discontinued, clozapine started at 25qd, stepwise increase until improvement or side effects occured. Clinical examinations twice before start and at days 3,7,10,17 and 21 during titration period and 30 and 90 during follow up","severe PD tremor w/o satisfying response to conventional therapy",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Frazzitta et al. 2013","Effectiveness of an intensive rehabilitation treatment on different Parkinson's disease subtypes","Neuro Rehabilitation","2013","Quasi-experimental study","To evaluate whether different iPS-subtypes respond differently to physical excercise","physical_exercise",NA,NA,"four week cycle of physiotherapy with three daily sessions of one hour a. cardiovascular warm up, b. relaxation excercise c. muscle stretching, d. improving function of abdominal and sine muscles, e. secondary balance and gait excercise with stabilometric platform with visual cue and treadmill f. third occupational therapy for autonomy in daily iving activities). Examination by neurologists during OFF, i.e. after 12 hours medication withdrawal at baseline and at end of rehab treatment.","clinically probable iPS according to criteria by Gelb et al."," ability to walk without any physical assistanc"," MMST less than 26"," no comorbidity unrelated to iPS"," no vestibular or visual dysfunction limiting locomotion or balance"," stable antiparkinsonian medications stable for more than 8 weeks",NA,NA,"uncertain data according to tremor",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Friedman et al. 1997","Benztropine versus clozapine for the treatment of tremor in Parkinson's disease","Neurology","1997","Quasi-experimental study","To compare low-dose clozapine to benztropine for treatment of tremor in iPS","clozapine",NA,NA,"clozapine and benztropine repackaged into identical capsules. Tremor measured by UPDRS and Fahn-Tolosa-Marin tremor scale at baseline and every two weeks. Videotapes at baseline and at maximum dose. a. Benztropine first 0.75mg qd increased each week by 0.75 mg to twice daily regimen. b. Clozapine first 12.5mg qd, increased by 12.5mg to twice daily regimen. Maximum doses of a. 4.5mg benztropine or 75mg clozapine daily. Ceiling dose for 1 week and maximum duration for each arm six weeks with two week washout. Second arm with other drug (clozapine or benzperidine, respectively)","IPS according to unknown clinical criteria"," ability to give informed consent"," age from 21 to 80 years"," score greater than 1 in UPDRS tremor items",NA,NA,NA,NA,"blood dyscrasia history"," uncontrolled seizures"," orthostatic hypotension"," prostatism"," narrow angle glaucoma"," dopamine blocking drugs within three months of study entry"," intake of betablocker"," intake of alpha-metyl-dopa-reserpine"," concomitant medication with dopamine agonists, anticholinergics, amantadine or antihistamines"," other drugs associated wih agranulocytosis within preceeding four weeks"," significant adverse events with either anticholingergics or clozapine"," white blood count of less than 4000 per microliter"," drug abuse"," pregnant or lactating women"," female fertiles",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Parkinson Study Group (1999)","Low Dose Clozapine for the treatment of drug-induced psychosis in Parkinson's disease","N Engl J Med","1999","Randomised-controlled trial (RCT)","To evaluate effects of low-dose clozapine for treatment of drug-induced psychosis and motor functions of iPS-patients","clozapine",NA,NA,"Patients randomly assigned to a. clozapine or b. placebo, double blind evaluation for four weeks. Baseline physical examination. Clozapine started at 6.25mg qd, which could be increased once between weekly office visits. At end of fourth week all tests repeated. Possible doses of clozapine between from 6.25mg to 50mg qd","iPS according to clinical criteria, that is when three of four cardinal symptoms were present"," psychosis induced by antiparkinsonian drugs which were severe enough to require treatment"," duration of psychosis more than four weeks",NA,NA,NA,NA,NA,"history of leukopenia"," dopamine-blocking medication within three months before study"," neuroleptic drug adminstered as depot within one year before study"," change in anxiolytic or antidepressant medication within one month before study"," orthostatic hypotension"," previous intake of clozapine"," uncontrolled angina"," uncontrolled seizures"," aquired immunodeficiency syndrome",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Glass (2003)","High Dose Treatment of Parkinson's disease with alpha-Dihydroergocryptine","Akt Neurol","2003","Quasi-experimental study",NA,"dopamine_agonist",NA,NA,"individual dose of dihidroergocriptin as add-on to levodopa over 6 months","IPS according to unknown clinical criteria"," clinical decision to initiate or increase dosage of dihydroergocriptin",NA,NA,NA,NA,NA,NA,"Medication with concomitant dopamine agonist",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Goetz et al. 2000","Objective changes in motor function during placebo treatment in PD","Neurology","2000","Randomised-controlled trial (RCT)","examine frequency, temporal development and stability of objectively derived motor changes during placebo treatment in iPS-patients and to define clinical domains and demographic groups most affected","placebo",NA,NA,"Placebo treated group from randomized, multicentre, controlled clinical trial of monotherapy with ropinirole in iPS-patients without motor fluctuations. In 105 patients placebo-associated effects on motor parts of UPDRS was evaluated. Motor examination was divided into 4 categories: remor, bradykinesia, rigidity, gait and balance and midline function. Definition of placebo-associated improvement as improvement over baseline in motor UPDRS of at least .5 or a change in at least two motor itemts at any visits by more than two points.","early iPS according due unspecified clincal criteria"," Hoehn & Yahr stages 1 to 3"," motor symptoms of sufficient severity to warrant the introduction of dopaminergic therapy, but not received L-dopa or any dopaminergic agonist for more than 6 weeks prior to study entry","  other antiparkinsonian therapies, except selegiline, discontinued at least 4 weeks prior to study entry"," selegiline were required to remain on a stable dose of selegiline for 4 weeks prior to study entry and for the duration of the study.",NA,NA,NA,"treatment with vasodilators, antiarrhythmics, digoxin, calcium channel blockers, angiotensin-converting enzyme inhibitors, or other antihypertensive agents (excluding diuretics)"," previous treatment with ropinirole"," history of severe systemic disease, major psychosis, or signs of dementia"," history of severe dizziness or fainting"," diastolic blood pressure of less than 110mmHg"," recent history of alcoholism or drug dependence.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Haas et al. 2006","The effects of whole body vibration on motor symptoms in Parkinson's Disease","NeuroRehabilitation","2006","Quasi-experimental study","To study the effects of whole-body-vibration on motor symptoms in iPS","other",NA,NA,"Levodopa withdrawn for 12hours. Three successive test sessions with two patients at each session in parallel, cross-over design. a. whole body vibration with consecutive resting phase. b. first rest, than whole body vibration. UPDRS motor score at baseline and after treatments . Examiner was blinded for intervention. Whole body vibration with 5 series lasting one minute, frequency of 6Hz and amplitude of 3mm.","iPS according to unknown clinical criteria"," ability of unsupported stance",NA,NA,NA,NA,NA,NA,"signs of dementia"," disease impairing gait, stance or coordination",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hartelt et al. 2020","Parkinson's Diease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic effects and Predictors for Improvement","Journal of Clinical Mediine","2020","Quasi-experimental study","assess efficacy of PD-MCT and calculate predictors of improvement","physical_exercise",NA,NA,"Baseline assessment before start of training, Discharge clinical testing after two weeks and follow-up after 6 weeks.","IPS according to UK Brain Bank criteria",NA,NA,NA,NA,NA,NA,NA,"inability to take part in procedures",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hattori et al. 2020","Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.","Park Relat Disord","2020","Randomised-controlled trial (RCT)","To evaluate the efficacy and safety of rasagiline as monoherapy in iPS-patients","rasagiline",NA,NA,"After initial two-week single-blind run-in period, in which patients received placebo once daily, a 26-week double-blind treatment period was conducted which patients were randomized 1:1 to receive a. placebo or b. oral rasagiline 1 mg qd","IPS according to UK Brain Bank criteria"," age between 30 to 79 years"," Hoehn and Yahr stages of 1 to 3"," MDS-UPDRS scores of more than 14",NA,NA,NA,NA,"Any investigational drug within prior 90 days"," previous use of rasagiline"," MMSE of less than 24"," treatment with amantadine or an anticholinergic drug for more than 180 days"," treatment with selegiline, levodopa or dopamine agonists for more 90 days"," use of selegiline within 90 days of first visit, or of any medication containing levodopa, dopamine agonists, amantadine or anticholinergic drugs within 30 days of first visit"," Concomitant use of antidepressants",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Heinonen et al. 1989","Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long- term levodopa treatment","Acta Neurol. Scand.","1989","Randomised-controlled trial (RCT)","investigate the efficacy of selegiline in the treatment of various types of fluctuations in disability and the effect of selegiline on parkinsonian disability and on the daily levodopa dose needed","selegiline",NA,NA,"patients were randomized to receive a. selegiline hydrochloride or b. placebo. One tablet of 5.0mg was administered in the morning and the other at lunch time, whereas daily levodopa dosages were kept at pre-study levels as fat as possible. Yet, changes were allowed if parkinsonian disability or side-effects required","advanced iPS according to unknown diagnostic criteria"," end-of-dose fluctuations"," daily frequency of over six administrations of levodopa",NA,NA,NA,NA,NA,"marked dementia"," diseases influencing the absorption of medications"," allergies to the medications under investigation"," previous treatments with selegiline or dopamine agonist"," age over 80 years",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hellmann et al. 2008","Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease","Biomedicine and Pharmacotherapy","2008","Quasi-experimental study","Evaluate the extent of tremor suppression under apomorphine therapy","apomorphine",NA,NA,"After one week of domperidon treatment, medication was withdraw at least 12h. Apomorphine sc was administered at increasing dosage of1, 2, and 4mg. Assessment with UPDRS part III before apomorphine administration and 15 minutes after.","IPS according to unknown clinical criteria"," absence of motor fluctuations",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hiremath (2012)","Role of Matrabasti and Kapikacchu Beeeja Powder in Kampavata (Parkinson's Disease)","International Journal of Research in Ayurveda and Pharmacy","2012","Quasi-experimental study","To evaluate the effects of Mahamasha oil Matra (Enema) and Kapikacchu beeja (Mucuna pruriens seed) in Kampavata (iPS)","other",NA,NA,"Haritaki powder 10-15gm with lukewarm water at bed time before treatment, full body massage with bala oil followed by 15 min steam bath.  Mahamasha oil Matrabasti (enema) 70ml every day for nine days, Mucuna pruriens seeds powder 6gm tid with lukewarm water after meals for 48 days. Evaluation before treatment, on ninth day after completion of enema course and after completion of oral treatment at day 48","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"other systemic disorders and with other complications possibly interfering with treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hughes et al. 1990","Apomorphine in the Diagnosis and Treatment of Parkinsonian Tremor","Clin. Neuropharmacol.","1990","Quasi-experimental study","To compare the responses of rest tremor to single dose apomorphine and oral levodopa in 20 tremor-dominant IPS-patients","apomorphine"," levodopa",NA,"Antiparkinsonian medication paused for 12h, domperidone pre-treatment, first day afterwards 250mg levodopa with 25mg carbidopa. Second day apomorphine sc in 1.5, 3, 4.5mg doses at 30min intervals until tremor was supressed, dose limiting sight-effects were resported or maximum dose was achieved.","iPS according to unknown clinical criteria with tremor dominance",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ikeda et al. 2015","Preliminary study of zonisamide monotherapy in de novo patients with Parkinsons's disease","Neurol Clin Neurosci","2015","Quasi-experimental study","evaluate therapeutic effects of zonisamide monotherapy in early Parkinson's disease patients","zonisamide",NA,NA,"10 untreated patients (de novo) patients were given 25 mg Zonisamide daily for 1 month, 50 mg in month 2 and 3. UPDRS I-IV and tremor-related UPDRS (items 16 (II) ,20, 21(III)) examined every month.","iPS accordint to UK Brain Bank criteria"," no previous treatment with anti-parkinsonian medication",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Jankovic et al. 2014","Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial","Parkinsonism Relat. Disord.","2014","Randomised-controlled trial (RCT)","To analyse the efficacy of 1mg rasagiline monotherapy in early iPS","rasagiline",NA,NA,"Patients randomised to 4 groups: a. 1mg rasagiline qd, b. 2 mg rasagiline qd, c. and d. delayed start with placebo respectively. Double-blind placebo-controlled phase for 36 weeks.","IPS according to clinical diagnosis with at least two of the symptoms bradykinesia, tremor, rigidity without any other known or suspected cause of parkinsonism","unilateral onset and persistent asymmetry If tremor is not present"," stable clinical condition not requiring anti-PD treatment for the next 9 months",NA,NA,NA,NA,NA,"Age younger than 30 or older than 80 years"," loss of postural reflexes"," UPDRS Tremor score of 3 or greater in any limb"," Hoehn &Yahr Stage III or greater at screening"," freezing while walking"," features that tend to exclude PD as the cause of Parkinsonism (repeated strokes or head injurys, definite encephalitis, Sustained remission, Supranuclear gaze palsy, Cerebellar signs, Early severe autonomic involvement, Babinski's sign, cerebral tumour or communicating hydrocephalus, MPTP exposure)"," Oculogyric crises"," previous use of rasagiline or selegiline"," other anti-PD medication at any time prior to baseline"," clinically significant or unstable medical or surgical condition"," not well controlled hypertonus"," history of melanoma"," significant cognitive impairment as defined by MMSE score < 26"," psychiatric illness"," major depression [Beck Depression Inventory (short form) =15"," history of alcohol or substance abuse within the past 2 years"," experimental medications within 60 days prior to baseline"," Q10 (in daily doses > 300 mg) within 120 days prior to baseline"," sympathomimetics (including over-the-counter remedies - nasal or oral), dextromethorphan, pethidine or St. John's Wort within the 7 days prior to baseline"," antidepressants within 42 days prior to baseline"," ciprofloxacin, a potent CYP 1A2 inhibitor within 7 days prior to baseline"," MAO inhibitors including reserpine or methyldopa within the three months prior to baseline"," treatment with an anti-emetic or antipsychotic medication with central dopamine antagonist activity within the six months prior to baseline"," women who are not postmenopausal, surgically sterilized, or using adequate birth control [oral birth control pills, IUD, or a long acting injectable form of contraception, barrier methods alone (i.e., condom) are not sufficient]"," women of childbearing potential without a negative pregnancy test at screening"," nursing women"
"Jansen (1994)","Clozapine in the treatment of tremor in Parkinson's Disease","Acta Neurol. Scand.","1994","Quasi-experimental study","To evaluate antitremor effects of clozapine as add-on therapy for iPS-patients","clozapine",NA,NA,"Clozapine aditionally to usual antiparkinson medication. Starting dose 6.25mg qd, if necessary increase each third day with dose split to bid. Study duration of six months with evaluations every fortnight. Every 4 weeks UPDRS motor evaluation. Changes of other parkinson medication during study were not allowed.","iPS according to unknown clinical criteria"," troublesome tremor despite optimal antiparkinsonian treatment",NA,NA,NA,NA,NA,NA,"dementia with MMST less than 18 points"," history of neuropsychiatric illness"," psychosis"," vivid dreaming",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Jitkritsadakul et al. 2015","Exploring the effect of electrical muscle stimulation as a novel treatment of intractable tremor in Parkinson's disease","J. Neurol. Sci.","2015","Quasi-experimental study","To determine the efficacy of electrical muscle stimulation as a treatment for drug resistant tremor in iPS-patients","other",NA,NA,"Hand tremor at rest and during postural positions assessed with the tremor analysis device which resulted in tremor parameters such as peak magnitude, the root mean square of angular velocity, frequency, and the dispersion of tremor a. before and b. during EMS. EMS was administered with parameters determined by slowly raising pulse amplitudes until tetanic muscle contraction occurred without pain. Stimulation lasted 10secs.","iPS-patient according to UK Brain Bank criteria"," medically refractory type I tremor according to the MDS consensus paper"," irreponsiveness of tremor to more than two different medications",NA,NA,NA,NA,NA,"history of cardiac arrthythmia seizures or cerebral ischaemia"," pregnancy"," concomitant medication potentiating or attenuating tremor, including antihistamines, thyroid hormones, benzodiazepines, anticonvulsants, and illicit drugs"," subjects with implanted electrical devices, such as cardiac pacemaker, deep brain stimulation devices and intrathecal baclofen pumps",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Jost et al. 2008","Rasagilin im klinischen Alltag - Ergebnisse einer Anwendungsbeobachtung bei Parkinson-Patienten mit einer Kombinationstherapie","Fortschr Neurol Psychiat","2008","Quasi-experimental study","investigate efficacy and tolerability of rasagiline under conditions of daily living","rasagiline",NA,NA,"iPS-patients received 1mg rasagilin qd as add-on for four months. Clinical evaluation at beginning, after four weeks and after four months. Concomitant parkinsonian medication remained unaltered.","NA",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kadkhodaie et al. 2019","Effect of eccentric-based rehabilitation on hand tremor intensity in Parkinson disease","Neurol. Sci.","2019","Randomised-controlled trial (RCT)","evaluate Effect of eccentric-based rehabilitation on hand tremor intensity in iPS","physical_exercise",NA,NA,"Moderate eccentric training three days per week for six weeks with 35-45min per session and assisted by occupational therapist. Targets were elbow flexor, wrist flexor and extensors muscle groups. Each muscle group trained with three sets of 10 repetitions of eccentric contraction with 1-2min rest between sets.","iPS according to UK Brain Bank criteria"," Hoehn and Yahr stages 1 to 4"," visible hand tremor uni- or bilterally",NA,NA,NA,NA,NA,"comorbidity interfering with designed exercises"," lack of ability to complete excercise sessions",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kaut et al. 2011","Stochastic resonance therapy in Parkinson's disease","NeuroRehabilitation","2011","Randomised-controlled trial (RCT)","To assess the effects of stochastic whole body vibration","other",NA,NA,"Patients were randomly assigned to sham or experimental group. a. experimental group received 5 cycles of stochastic WBV on three days within five days. Cycle of five stimulus trains of 60s duration with a frequency of 6.5Hz and 60s resting time in between. b. control group received sham treatments with 1Hz (lowest frequency available).","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"signs of dementia"," atypical or secondary parkinsonism"," nephrolithiasis"," relevant orthopedic disease","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"King et al. 2009","Short-term effects of vibration therapy on motor impairments in Parkinson's disease","NeuroRehabilitation","2009","Randomised-controlled trial (RCT)","To evaluate the influence of vibration on motor symptoms and functional measures in iPS by delivering sound waves to the whole body","other",NA,NA,"Vibrations applied by physioacoustic method. Arm chair run by software produced controlled sound vibrations from six speakers for whole body involvement in effect. Adminstered in 5 consecutive series lasting one minute each, one minute rest in between. Assessment by UPDRS first. Two participants studied in parallel, one first vibration, other one started with rest in single-blind cross-over design.","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"signs of dementia"," diseases imparing gait or coordination",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Koller et al. 1987","Adjuvant Therapy of Parkinsonian tremor","Arch. Neurol.","1987","Quasi-experimental study","To study the effects of propranolole, primidone and clonazepam ass add-on therapy for iPS tremor","propranolole"," primodone"," clonazepam","Patients received either a. 80mg  qd for 1 week and 160mg afterwards, b. primidone 50mg qd for 1 week, 125mg for another week and 250mg qd afterwards), or c. clonazepam 1mg qd at first week and increase of 1mg weekly up to 4mg qd. Tremor evaluated after highest dose intake for one month.","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Koller et al. 1987.1","Adjuvant Therapy of Parkinsonian tremor","Arch. Neurol.","1987","Quasi-experimental study","To study the effects of propranolole, primidone and clonazepam ass add-on therapy for iPS tremor","propranolole"," primodone"," clonazepam","Patients received either a. 80mg  qd for 1 week and 160mg afterwards, b. primidone 50mg qd for 1 week, 125mg for another week and 250mg qd afterwards), or c. clonazepam 1mg qd at first week and increase of 1mg weekly up to 4mg qd. Tremor evaluated after highest dose intake for one month.","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Koller et al. 1987.2","Adjuvant Therapy of Parkinsonian tremor","Arch. Neurol.","1987","Quasi-experimental study","To study the effects of propranolole, primidone and clonazepam ass add-on therapy for iPS tremor","propranolol"," primodone"," clonazepam","Patients received either a. 80mg  qd for 1 week and 160mg afterwards, b. primidone 50mg qd for 1 week, 125mg for another week and 250mg qd afterwards), or c. clonazepam 1mg qd at first week and increase of 1mg weekly up to 4mg qd. Tremor evaluated after highest dose intake for one month.","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kulisevsky et al. 2002","A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease","Clin. Neuropharmacol.","2002","Randomised-controlled trial (RCT)","To test for the effects of stable plama levels of theophylline on the long-duration response and the short-duration response to levodopa in advanced iPS-patients","adenosine_antagonist",NA,NA,"Treatment for 15 days with a. 150mg theophylline bid and b. placebo bid; dosage was adjusted according to plasmatic levels during first week. After 15 days levodopa washout (but not theophylline or placebo) for four days and, finally, levodopa challenge was performed.","iPS-patient according to unknown clinical criteria"," treatment with levodopa as only medication at least two months before entering the trial",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Laihinen et al. 1992","Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson’s disease","Acta Neurol. Scand.","1992","Randomised-controlled trial (RCT)","Compare therapeutic efficacy of lisuride with bromocriptine","dopamine_agonist",NA,NA,"a. lisuride and placebo or b. bromocriptine and placebo as add-on therapy to levodopa or anticholinergics was administered. Patients randomly assigned to groups and optimal dosage found within 4-8 weeks. Therapy continued for further four weeks. After wash-out period of max 2 weeks, each group received the other drug and placebo.","iPS according to unknown clinical criteria"," long-term levodopa treatment and motor fluctuations",NA,NA,NA,NA,NA,NA,"age of more than 80 years",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Levin et al. 2010","Effect of dopamine agonist pramipexole (mirapex) on tremor, affective disorders and quality of life in patients with Parkinson’s disease","Zh Nevrol Psikhiatr Im SS Korsakova","2010","Quasi-experimental study","To evaluate the effects of pramipexole on motor symptoms in iPS-patients","levodopa",NA,NA,"six months pramipexole therapy as add-on or monotherapy. Individual dose based on clinical impression","iPS according to UK Brain Bank criteria",NA,NA,NA,NA,NA,NA,NA,"signs of dementia"," atypical parkinsonian syndromes"," short psychological status scale scores of less than 25"," concomitant allergies"," psychosis"," severe depression"," comorbid medical or neurological conditions",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Lew (2013)","Rasagiline treatment effects on parkinsonian tremor","Int. J. Neurosci.","2013","Randomised-controlled trial (RCT)","To present data illustrating effect of rasagiline on tremor in iPS-patients with data from four the ADAGIO study","rasagiline",NA,NA,"Two phases of trial each of 36 weeks duration. Randomisation to four groups, either with delayed-onset or immediate start of rasagiline. Only 1mg arm along with two placebo groups is compared. Specifically, patients received a. placebo or b. rasagiline 1mg qd for 36 weeks and consecutively both groups rasagiline. No other medication was allowed according to the protocol","iPS patients with at least two cardinal motor symptoms"," age betweeen 30 and 80 years","  Hoehn and Yahr stage of three or less","",NA,NA,NA,NA,"Concomitant medication with any antiparkinsonian medication for more than three weeks"," medication with rasagiline or selegiline at any dose or medication with coenzyme Q10 with more than 300mg daily in the previous 120 days"," Atypical or secondary parkinsonism"," disease duration of more than 18 months","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Lew (2013).1","Rasagiline treatment effects on parkinsonian tremor","Int. J. Neurosci.","2013","Randomised-controlled trial (RCT)","To present data illustrating effect of rasagiline on tremor in iPS-patients with data from four the TEMPO study","rasagiline",NA,NA,"Patients received a. placebo or b. rasagiline 1mg qd. After one week of titration study could be increased to 2mg (data not included). Outcomes were assessed after further 25 weeks. No changes in medication were allowed according to the protocol","iPS patients with at least two cardinal motor symptoms"," aged of 35 years or more","  Hoehn and Yahr stage of three or less","",NA,NA,NA,NA,"Atypical or secondary parkinsonism"," unstable medical problems including congestive heart failure of New York Heart Association class II or greater"," psychiatric conditions that compromise the ability to give informed consent","  subjects with significant cognitive impairment as defined by MMSE score < 23"," subjects with clinically significant depression"," subjects treated with levodopa, dopamine agonists, selegiline or amantadine"," Concomitant medication with antidepressants except for  amitryptiline, paroxetine, sertraline, fluovoxamine or trazodone",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Li et al. 2018","Acupuncture modulates the Cerebello-Thalamo-Cortical Circuit and Cognitive Brain Regions in Patiens of Parkinson's Disease with Tremor","Front. Aging Neurosci.","2018","Randomised-controlled trial (RCT)","To investigate the effects of acupuncture on tremor in iPS-patients","other",NA,NA,"Patients randomly assigned to a, true acupuncture group - TAG,  b. sham acupuncture group - SAG or c. waiting group - WG. a. stainless steel needles inserted for 2.0-3.0cm into DU2, that is Baihui, GB20, that is Fengchi and Chorea-Tremor Controlled Zone. Reinforcing reducing method performed every 10min. within 30min needle retention time. b. Needles next to above named points inserted, no manipulation to needle performed. c. 12 weeks medication only, afterwards true accupuncture.","iPS according to UK Brain Bank criteria"," tremor at rest in at least one upper or lower extremity (item 20 in the UPDRS)",NA,NA,NA,NA,NA,NA,"secondary parkinsonism"," atypical parkinsonism"," advanced iPS, that is Hoehn and Yahr stages of more than 4"," age less than 45 or greater than 80 years"," history of other neurological disorders or head trauma"," left handedness"," cognitive impairment"," contraindications for fMRI",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Lieberman et al. 1997","Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study.","American Academy of Neurology","1997","Randomised-controlled trial (RCT)","To compare the efficacy, safety and tolerability of pramipexole to placebo in advanced iPS with motor fluctuations under levodopa","dopamine_agonist",NA,NA,"At first visit every recording of concomitant medication. At visit two randomization to a. pramipexole or b. matching placebo. Up to seven weeks ascending dose phase during which pramipexole was titrated from 0.375mg to 4.5mg tid. Dosage increased incrementally until stabile clinical examination or AE. Dose of levodopa and carbidopa could be reduced if possible. Maintenance dose phase up to 24 weeks.","iPS according to unknown clinical criteria"," age of at least 30 years"," Hoehn and Yahr stage 2 to 4"," motor fluctuations"," stable levodopa dosage for at least 30 days",NA,NA,NA,"atypical or secondary parkinsonism"," cognitive impairment"," second- or third-degree AV block or SSS"," resting heart rate below 50 BPM"," congestive heart failure"," myocardial infarction within 6 months of the 
study"," clinically significant liver or renal disease"," active 
neoplastic disease"," history of stereotactic brain surgery",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Lotan et al. 2014","Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study","Clin. Neuropharmacol.","2014","Quasi-experimental study","NA","cannabis",NA,NA,"Patients tested in OFF before taking their regular medication. UPDRS was rated among others tests ans questionnaires. Afterwards smoking of regular dosis cannabis with measurements repeated 30 minutes later by two raters","iPS according to unknown clinical criteria"," permission to smoke cannabis from Israel Minstry of Health as add-on therapy because of insufficient iPS medication or to treat combat pain"," treatment with cannabis on daily basis for at least two motnhs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Macht et al. 2000","Effects of Relaxation Training and Music in Parkinson's Disease","Verhaltenstherapie","2000","Randomised-controlled trial (RCT)","To compare the effects of progressive muscle relaxation (PMR) and listening to music on motor symptoms in iPS-patients","physical_therapy",NA,NA,"Patients randomly assigned to two groups, a. Five sessions of Progressive Muscle Relaxation or b. five sessions listening to ""Kleine Nachtmusik"" for twenty minutes on five consecutive days. Tremor assessment with the ""tremormeter""","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"Hoehn and Yahr stage greater than 4"," severe depression or other psychiatric disorder"," experience with relaxation techniques before study inclusion",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Maeda et al. 2015","Zonisamide in the early stage of Parkinson's disease.","Neurol. Clin. Neurosci.","2015","Quasi-experimental study","investigate effects of zonisamide on the early stages of iPS","zonisamide",NA,NA,"After first evaluation patients received 25mg zonisamid qd. Visited after 4, 12, 20 and 28 weeks.","iPS according to UK Brain Bank criteria"," disease duration of less than 3 years"," levodopa and decarboxylase inhibotor only or only small amounts of dopamine agonists"," MMST of less than 23",NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mailland et al. 2011","Alpha-dihydroergocryptine in the Long-term Therapy of Parkinson’s Disease","Drug Res. formerly Arzneim.-Forsch.","2011","Quasi-experimental study","To investigate the safety of alpha-DHEC","dopamin_agonist",NA,NA,"patients received alpha-DHEC over six months, initial dose 10mg qd, increased up to median dose of 30mg qd. at first three months or 40 mg month 4 to 6 qd.","iPS according to unknown clinical criteria"," treatment with levodopa and alpha-DHEC",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Malsch et al. 2001","Monotherapy of Parkinson's disease with budipine: A randomized double-blind comparision to amantadine.","Fortschr Neurol Psychiatr","2001","Randomised-controlled trial (RCT)","To compare budipine and amantadine with respect to efficacy and safety in monotherapy of mildly to moderately affected iPS-patients","budipine"," amantadine",NA,"Patients randomly assigned to a. budipine or b. amantadine. Evaluation by Webster-Rating-Scale after 1, 2, 3, 4, 6, 8 and 12 weeks. Bradykinesia, rigidity and tremor separately analysed.","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mark et al. 1989","Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.","Ann. Clin. Lab. Sci.","1989","Quasi-experimental study","To observe the long-term effects of controlled-release levodopa on motor symptoms of iPS-patients","levodopa",NA,NA,"Controlled-release levodopa at individual dosage and scheme was administered and changes were assessed after 12 months. Adjustments of other medication was allowed","iPS according to unknown clinical criteria"," presence of motor fluctuations"," continued use of extended release levodopa formulation after participation in previous RCT",NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mentenopoulos et al. 1989","Piribedil Therapy in Parkinson's Disease Use of the Drug in the Retard Form","Clin. Neuropharmacol.","1989","Quasi-experimental study","evaluate the efficacy of piribedil in iPS-patients","dopamine_agonist",NA,NA,"previous antiparkinsonian medication including levodopa, anticholinergics and amantadine remained stable. Over 20 weeks pirbedil was administered starting with 50mg in cr formulation, weekly increment of 50mg up to maxmum of 200mg daily. Weekly examinations during first month, afterwards monthly","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mizuno et al. 1995","Pergolide in the treatment of Parkinson's Disease","Neurology","1995","Quasi-experimental study","To evaluate the efficacy and safety of pergolide for iPS-patients","pergolide",NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mizuno et al. 1995.1","Pergolide in the treatment of Parkinson's Disease","Neurology","1995","Randomised-controlled trial (RCT)","To evaluate the efficacy and safety of pergolide for the treatment of iPS-patients","pergolide"," bromocriptine",NA,"Short-term double-blind study: 345 Patients randomly assigned to a. pergolide or b. bromocriptin. Up to day 14 fixed amount of either pergolide or bromcriptin. maintenance dosage thereafter determined for individual patient.","NA",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mizuno et al. 2017","A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early parkinson disease","Clin Neuropharmacol","2017","Randomised-controlled trial (RCT)","To evaluate the efficacy and safety of selegiline monotheray in patients with iPS","selegiline",NA,NA,"Subjects were randomised to a. placebo or b. oral selegline. At first two weeks 1 mg qd was administered, at weeks 2-3 2.5mg bid, week 4-5 5mg in the morning and 2.5mg in the afternoon and from week 6 onwards 5mf bid","IPS according to clinical diagnosis according to Brain Bank criteria"," age between 20 and 75 years"," motor symptoms for less than five years"," hoehn and yahr stage of 1 to 3"," no therapy with antiparkinson agents or less than 12 weeks of treatment"," updrs scores of ten or greater",NA,NA,"Treatment with pethidine, tramadol, tricyclic antidepressants, selective serotonin reuptake inhibitors"," certain antihistaminic drugs or drugs possibly affecting PD symptoms within three weeks before first medication intake"," patients suffereing from concomitant impaired consciousness, hallucinations, delusions and abnormal disorders"," therapy for epilepsy"," patients with serious complications, e.g., cardiovascular, renal, hepatic or hematologic disorders"," patients with past or current abuse of central nervous system stimulants such as antihypnotic drugs or cocaine"," female patients whoe were pregnant or lactating or were willing to become pregnang during the trial"," patients who had participated in other clinical trials with selegiline",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Moeller et al. 2005","Long-term Efficacy and Safety of Pramipexole in Advanced Parkinson's Disease: Results From a European Multicenter Trial","Mov. Disord.","2005","Randomised-controlled trial (RCT)","To compare the efficacy, safety and tolerability of pramipexole compared to placebo in advanced iPS-patients","dopamine_agonist",NA,NA,"30 days before randomization washout of dopamine agonists, iPS-patients randomized to a. pramipexole and b. placebo. Ascending dose phase of seven weeks, maitenance phase of up to 24 weeks.","advanced iPS according to unknown clinical criteria"," presence of motor fluctuations under levodopa treatment as end-of-dose phenomena",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Montastruc et al. 1999","A Randomized, Double-Blind Study of a Skin Patch of a Dopaminergic Agonist, Piribedil, in Parkinson’s Disease","Mov. Disord.","1999","Randomised-controlled trial (RCT)","to evaluate the pharmacologic activity of one and two transdermal patches of piribedil in combination with L-dopa on the motor symptoms of iPS","dopamine_agonist",NA,NA,"Transdermal patches with 30-cm2 matrices containing 50mg micronized piribedil and an adhesive strip were used, wheras placebo was of matching appearance. Two patches were applied daily at the same time on the dorsal surface of the arm, one below the other, on alternating arms at each application. If a patch became unstuck over more than half its area before the scheduled removal time, a replacement patch was applied to the same site. During the selection period, patients were treated for seven days with two placebo patches. At inclusion, randomization into three parallel treatment groups: a. two piribedil patches, b. two placebo patches, or c. one piribedil and one placebo patch.","iPS according to unknown clinical criteria"," aged between 35 and 80 years"," Hoehn and Yahr stages 1 to 3"," disease duration of less than 10 years"," medication with levodopa for at least six months at dosages of more than 800mg qd divided into less than six dosages"," levodopa regime unchanged for at least one month before inclusion"," unchanged motor status and mood over two weeks before entering the study in terms of both Hoehn and Yahr stage and investigator impression"," inadequate clinical response to current therapies as shown by persistent parkinsonian symptoms","neurodegenerative disorders"," secondary or atypical Parkinsonism"," systemic diseases as revealed by medical or laboratory examination"," patients whose placebo patches failed to stick during the selection period"," previous treatment with dopamine agonists if not withdrawn at least one month before enrolment"," therapy with anticholinergics and selegiline initiated  less than one month before study enrolment"," changes of dopamine agonist dosage during the trial",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mueller et al. 2003","Treatment of Parkinson’s disease with controlled release levodopa/carbidopa: An open observational trial","Psychoneuro","2003","Quasi-experimental study","To describe the effects of levodopa and carbidopa in an extended release formulation","levodopa",NA,NA,"Administration of levodopa and carbidopa in a controlled release formulation at individually accepted dosages.","iPS according to unknown clinical criteria"," Hoehn and Yahr stages 1 to 4",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mueller et al. 2003.1","Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease","Neurosci. Lett.","2003","Quasi-experimental study","To determine the efficacy of intravenous amantadine on motor symptoms of iPS-patients","amantadine",NA,NA,"three infusions of 200mg amantadine sulphate on three consecutive days, assessment at day four","iPS according to unknown clinical criteria"," no prior medication with amantadine"," lack of unpredictable motor fluctuations",NA,NA,NA,NA,NA,"signs of dementia"," concomitant depression"," history of cerebral lesions or significant atrophy"," medication with neuroleptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Nakanishi et al. 1991","A nationwide collaborative study on the long-term effects of bromocriptine in patients with parkinson’s disease: The fourth interim report","Eur. Neurol.","1991","Quasi-experimental study","To evaluate long-term effects of bromocriptine on motor symptoms of iPS-patients","dopamine_agonist",NA,NA,"bromocriptine as mono-therapy in de-novo pat. OR randomized: bromocriptine as add-on to levodopa or optimization of dopa mono therapy, mono to combi in the initial mono bromocriptine group possible","iPS according to unknown clinical criteria"," start on bromocriptine or already on medication thereof",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Navan et al. 2003","Double-blind, single dose, cross-over study of the effects of pramipexole, Pergolide, and Placebo on Rest Tremor and UPDRS part III in Parkinson's Disease","Mov. Disord.","2003","Randomised-controlled trial (RCT)","To compare the effects of single oral dose of a. pramipexole b. pergolide or c. placebo on parkinsonian tremor and part III of the UPDRS","pramipexole"," pergolide",NA,"Three study days with one week in between. All participants received domperidone 24 hours before start of trial treatment, whereas no anti-parkinsonian medication were allowed from midnight onwards before the study. After baseline assessment, intake of 500 µg of pramipexole or pergolide, respectively or one pill of placebo. Assessment on half-hourly intervals for four hours with double-blind protocol.","iPS according to UK Brain Bank Criteria"," rest tremor of at least one upper limb with an intensity of at least 2 of 10"," no previous intake of direct acting dopamine agonist",NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Navan et al. 2003.1","Double-blind, single dose, cross-over study of the effects of pramipexole, Pergolide, and Placebo on Rest Tremor and UPDRS part III in Parkinson's Disease","Mov. Disord.","2003","Randomised-controlled trial (RCT)","compare effects of single oral dose of a. pramipexole b. pergolide or c. placebo on parkinsonian tremor and part III of the UPDRS","pramipexole"," pergolide",NA,"Three study days with one week in between. All participants received domperidone 24 hours before start of trial treatment, whereas no anti-parkinsonian medication were allowed from midnight onwards before the study. After baseline assessment, intake of 500 µg of pramipexole or pergolide, respectively or one pill of placebo. Assessment on half-hourly intervals for four hours with double-blind protocol.","iPS according to UK Brain Bank Criteria"," rest tremor of at least one upper limb with an intensity of at least 2 of 10"," no previous intake of direct acting dopamine agonist",NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Navan et al. 2003.2","Randomized, Double-blind, 3-Month Parallel Study of the Effects of Pramipexole, Pergolide, and Placebo on Parkinsonian Tremor","Mov. Disord.","2003","Randomised-controlled trial (RCT)","To compare anti-tremor effects of pramipexole, pergolide and plaebo in iPS-patients","pramipexole"," pergolide",NA,"iPS-patients (n=30) randomly assigned to a. pramipexole b. pergolide or c. placebo. Pre-Treatment with domperidone and after baseline assessment dose gradually titrated upward in 9 levels that is placebo or 1.5mg pramipexole or 1.5mg pergolide tid. Monthly assessment including verbal fluency task while tremor was scored and measured.","IPS according to UK Brain Bank Criteria"," symptomatic tremor in at leasrt one upper limb with severitiy on validated tremor rating scale of more than two of ten"," no previous medication with direct acting dopamine agonist",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Nigro et al. 2019","Apomorphine-induced reorganization of striato-frontal connectivity in patients with tremor-dominant Parkinson’s disease","Parkinsonism Relat. Disord.","2019","Quasi-experimental study","To assess the acute effects of apomorphine versus placebo on tremor and functional connectivity","apomorphine",NA,NA,"Subjects received a. 1mg apomorphine i.v. and b. placebo i.v. within two days after medication withdrawal in a cross-over and randomised design. Measurement 60 minutes after administration","iPS according to UK Brain Bank criteria"," right handedness"," rest tremor of more than 2 points in the UPDRS",NA,NA,NA,NA,NA,"signs of dementia"," depression"," concominant neurological diseases"," MRI related exclusion criteria",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Nomoto et al. 2018","Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post-hoc analysis of randomized, double-blind, placebo-controlled trials","J. Neurol.","2018","Randomised-controlled trial (RCT)","To examine the efficacy and safety of rotigotine treatment for elderly and non-elderly PD patients separately","rotigotine",NA,NA,"After a four week screening period, there was an eight week titration period and a four week maintenance period, a two week taper period, and, finally, a one week safety follow-up period. Patients received either a. rotigotine transdermal patches with 2 mg/24 hours or b. placebo patches. Weekly increments of 2mg up to a maximum of 16 mg qd during titration period.","iPS according to UK Brain Bank criteria"," no concomitant treatment with levodopa"," Hoehn and Yahr stages I to III","",NA,NA,NA,NA,"Presence of psychiatric symptoms such as confusion, hallucinations, delusions, excitation, delirium and abnormal behavior"," symptomatic orthostatic hypotension"," history of epilepsy"," complications or history of serious cardiac disease and or arrhythmia"," severe renal or hepatic impairments"," deep brain stimulation lead surgery"," signs of dementia"," treatment with levodopa for more than 6 months by the time of informed consent"," concomitant treatment with substances that could possibly affect PD symptoms from at least four weeks before the date of first treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Nomoto et al. 2018.1","Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post-hoc analysis of randomized, double-blind, placebo-controlled trials","J. Neurol.","2018","Randomised-controlled trial (RCT)","To examine the efficacy and safety of rotigotine treatment for elderly and non-elderly PD patients separately","rotigotine",NA,NA,"post hoc analysis of all randomized, double-blind, placebo-controlled trials with focus on rotigotine in Japan. Two combination-therapy trials (levodopa plus rotigotine vs levodopa + placebo) included.","NA",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Nutt et al. 2007","Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial","Arch. neurol","2007","Randomised-controlled trial (RCT)","Confirm beneficial effects of pramipexole on core symptoms of iPS with focus on tremor; assess antidepressant effects of pramipexole; demonstrate practicability of Snaith-Hamilton-Pleasure Scale, Tremor impact scale and Short Parkinson's Evaluation Scale","other",NA,NA,"Admission to inpatient stay for four days, during which dosage was titrated to .4mg per kg tid, while other medication was reduced if possible. Subjects returned to two visits after one and two weeks during which the efficacy was tested. Comparisons between measurements at 8am and 8pm. Randomisation to a. methylphenydate and b. placebo","iPS-patient according to unknown clinical criteria"," responsiveness to levodopa"," normal vital signs and general medical history and examination",NA,NA,NA,NA,NA,"unstable medical problems"," hypertension"," cardiac arrhythmias"," Mini-Mental State Examination score of less than 24"," intake of monoamine oxidase inhibitors",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Olanow et al. 1987","Double-blind controlled study of pergolide mesylate as an adjunct to sinemet in the treatment of Parkinson's disease","Adv Neurol.","1987","Randomised-controlled trial (RCT)",NA,"dopamine_agonist",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Olson et al. 1997","Gabapentin for Parkinsonism: A double-blind, placebo-controlled, crossover trial","Am J Med.","1997","Randomised-controlled trial (RCT)","To evaluate the effects of a single dose gabapentin on motor symptoms of iPS-patients","other",NA,NA,"six doses of 400mg gabapentin or placebo over three days, eleven days wash-out, crossover","parkinsonism"," age from 35 to 85 years"," Hoehn and Yahr stage 2.5 to 5",NA,NA,NA,NA,NA,"pregnancy"," liver disease"," kidney disease"," bone marrow disease"," dystonia"," concomitant Huntington disease"," essential tremor"," cerebellar symptoms",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Parkinson Study Group (2007)","Pramipexole in Levodopa-treated Parkinson Disease Patients of African, Asian, and Hispanic Heritage","Clin. Neuropharmacol.","2007","Randomised-controlled trial (RCT)","To evaluate the tolerability, safety, and efficacy of pramipexole in iPS-patients who identified themselves as members of any of three US census designations: African, Hispanic, or Asian.","pramipexole",NA,NA,"a. pramipexole or b. identical appearing placebo was initiated at 0.375mg qd and escalated during first six weeks to a maximal dosage of 4.5mg or until occurence of intolerable side-effects. Medication was administered t.i.d, with subjects receiving 0.375 mg daily during weeks 1 and 2, 1.5mg daily during weeks 3 and 4, 3.0mg daily during week 5, and 4.5 mg from week 6 onwards. In case of side-effects, dosage was decreased temporarily to the prior tolerable level, and titration was resumed to the maximally tolerated dosage. Subjects were maintained at final dosage for four week maintenance period. If disabling parkinsonism developed during maintenance, levodopa dosage was adjusted.","iPS according to UK Brain Bank criteria"," subjects self-identified as being of African, Hispanic, or Asian heritage"," age of at least 30 years"," treatment with stable dosage of levodopa for at least one month before randomization"," Hoehn and Yahr stages 2 to 4",NA,NA,NA,"atypical parkinsonian syndromes"," Mini Mental State Examination of less than 21"," history of psychosis"," occurrence of a seizure within year before screening"," clinically significant hepatic or renal disease"," clinically significant coronary artery disease, bradycardia, or congestive heart failure"," myocardial infarction within six months of randomization"," symptomatic orthostatic hypotension"," active neoplastic disease"," medication with dopamine agonist within two months before inclusion"," use of unstable dose of CNS active therapies 60 days before randomization"," positive hepatitis B screening",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Petramfar et al. 2020","Efficacy of oral administration of licorice as an adjunct therapy on improving the symptoms of patients with Parkinson’s disease, A randomized double blinded clinical trial","J Ethnopharmacol","2020","Randomised-controlled trial (RCT)","To investiate the effects of liquorice on symptoms of iPS-patients","other",NA,NA,"six months of 136 mg polyphenol-rich extract of licorice td versus placebo intake","iPS according to unknown clinical criteria"," age between 30 and 80"," disease duration of less than seven years"," Hoehn and Yahr stage of less than 4"," no medication changes in month before study inititation",NA,NA,NA,"mediaction with warfarin or SSRI or MAO-inhibitors or diuretics"," concomitant diabetes"," history of stroke"," heart disease"," liver disease"," renal disease"," uncontrolled arterial hypertension"," hypokaliaemia"," pregnancy"," breast feeding",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Pogarell et al. 2002","Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study","J. Neurol. Neurosurg. Psychiatry","2002","Randomised-controlled trial (RCT)","To compare the tremorlytic properties of pramipexole to those of placebo as add-on medication in iPS-patients","dopamine_agonist",NA,NA,"two weeks screening period, random assignment to a. Placebo or b. pramipexole under double blind conditions, ascending dose interval of seven weeks to 0.375 and 4,5mg qd pramipexole or matching placebo, four weeks maintenance period, one week dosis reduction. Additional antiparkinsonian medication stable 30 days before randomisation and during study.","iPS according to UK Brain Bank criteria"," marked and drug resistant tremor defined by sum of 6 at one side or 8 on both sides in items 16,20 and 21 of UPDRS",NA,NA,NA,NA,NA,NA,"atypical parkinson syndrome"," signs of severe dementia"," epilepsy"," previous neurosurgery"," electroconvulsive therapy within 90 days before randomisation"," severe other physical illness"," symptomatic hypotension",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Pollok et al. 2009","Levodopa affects functional brain networks in Parkinsonian resting tremor","Mov. Disord.","2009","Quasi-experimental study","investigate effects of single dose of levodopa on rest state connectivity in MEG and on EMG tremor characterstics","levodopa",NA,NA,"200mg of fast-acting levodopa versus off-state","iPS according to unknown clinical criteria"," presence of rest tremor",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Przuntek et al. 2002","Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen","Arch. Neurol.","2002","Randomised-controlled trial (RCT)","To demonstrate the efficacy of budipine as add-on on motor symptoms in iPS-patients","budipine",NA,NA,"Titration of a. budipine up to 60mg qd or b. placebo over five weeks and administered at stable dosages for eleven weeks","iPS according to UK Brain Bank criteria",NA,NA,NA,NA,NA,NA,NA,"unpredictable fluctuations"," relevant cardiac or hepati or gastrointestinal or pulmonary or metabolic or renal diseases"," concomitant psychiatric disorders"," therapy with dopamine antagonists",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Rabey et al. 1994","Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson’s disease","J. Neural Transm.  - Park Dis Dement Sect","1994","Quasi-experimental study","To evaluate the effects of memantine on motor symptoms of iPS-patients","memantine",NA,NA,"Subjects received increasing dosages of memantin until maximal dosage of 30mg qd which was maintained over 28 days","iPS according to unknown clinical criteria"," presence of motor fluctuations",NA,NA,NA,NA,NA,NA,"renal or hepatic or cardiovascular or respiratory or gastrointestinal diseases"," signs of dementia"," concomitant psychosis",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Rahimi et al. 2015","Effective management of upper limb parkinsonian tremor by incobotulinumtoxin-A injections using sensor-based biomechanical patterns","Tremor Other Hyperkinet Mov (N Y)","2015","Quasi-experimental study","evaluate safety and efficacy of kinematically-guided, indivldualized incobotulinumtoxin  A injections for upper limb tremor in iPS- and ET-patients","botulinumtoxin",NA,NA,"EMG-guided individualized injections of incobotulinum toxin into unilateral arm  after kinematic tremor assessment with sensors at wrists, elbows and shoulders; four injections every 12 weeks, mean dose approximately 150U","iPS according to UK Brain Bank criteria"," Hoehn and Yahr stages from 1 to 3"," stable medication for at least six months"," no previous treatments with botulinum toxin",NA,NA,NA,NA,"history of stroke"," contraindications for botulinum toxin injections"," pregnancy"," intake of lithium or valproate",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Rascol et al. 1988","Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: A double-blind cross-over placebo-controlled trial","Neurology","1988","Randomised-controlled trial (RCT)","To determine whether deprenyl can improve clinical effects of a single standard dose of levodopa, and whether two weeks of deprenyl treatment could improve parkinsonian patients motor scores","selegiline",NA,NA,"a. selegiline 10mg daily or b. placebo in a controlled double-blind cross-over design for two successive periods of two weeks each.","iPS according to unknown clinical criteria"," treatment with levodopa at a stable dosage for at least two months before entering the trial"," levodopa medication had to remain unchanged during the study"," other antiparkinsonian drugs were allowed if their dosages remained stable for the same period.",NA,NA,NA,NA,"random motor fluctuations"," “on-off’ phenomena"," freezing of gait"," clinical evidence of dementia",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Reichmann et al. 2002","[Pramipexole in Parkinson disease Results of a treatment observation]","Nervenarzt","2002","Quasi-experimental study","To observe the efficacy and safety of pramipexole in clinical practice","dopamine_agonist",NA,NA,"pramipexole in individualized daily dosage of up to 3.15mg qd over nine weeks with unaltered dosage within last five weeks","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Reichmann et al. 2003","Pramipexole in Routine Clinical Practice. A Prospective Observational Trial in Parkinson's Disease.","CNS drugs","2003","Quasi-experimental study","To confirm the beneficial effects of pramipexole on core symptoms of iPS with focus on tremor, to assess antidepressant effects of pramipexole and to demonstrate the practicability of the Snaith-Hamilton-Pleasure Scale, Tremor impact scale and Short Parkinson's Evaluation Scale","dopamine_agonist",NA,NA,"Treatment details from 298 German centres and 657 iPS-patients. Tretament with pramipexole initiated by local neurologist with 0,35mg td, increased weekly up to 4,5mg over 4 weeks. Clinical evaluation at baseline, at end of titration phase and at end of observation.","iPS-patient according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Reichmann et al. 2005","[Practical experience on improving activities of daily living competence in Parkinson’s patients treated with ropinirole Results of a applied study]","Nervenarzt","2005","Quasi-experimental study","Observe efficacy and safety of ropinirole in iPS-patients","dopamine_agonist",NA,NA,"Individualised dosage of ropinirole was increased up to 24mg qd over twelve weeks. Stable dosage within last six weeks of observation","iPS according to unknown criteria"," less than 4mg ropinirole qd",NA,NA,NA,NA,NA,NA,"allergies"," liver or renal failure"," pregnancy",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Reichmann & Jost (2010)","Efficacy and tolerability of rasagiline in daily clinical use - A post-marketing observational study in patients with Parkinson’s disease","Eur J Neurol","2010","Quasi-experimental study","observe the efficacy and tolerability of rasagiline as mono and combination therapy in large population of iPS-patients","rasagiline",NA,NA,"Administration of rasagiline 1mg qd as monotherapy or as add-on therapy","iPS according to unknown clinical criteria"," clinical decision to prescribe rasagiline",NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ridgel et al. 2012","Active-assisted cycling improves tremor and bradykinesia in Parkinson’s disease","Arch Phys Med Rehabil","2012","Quasi-experimental study","To investigate effects of a single session of active assisted cycling on tremor and bradykinesia of iPS-patients","physical_therapy",NA,NA,"Subjects were compared at baseline and after half an hour active assisted cycling using a motomed with 75rpm and subjects being asked to pedal 80-85 rpm. Recordings in OFF medication state","iPS according to unknown clinical criteria"," Hoehn and Yahr stages 1 to 3",NA,NA,NA,NA,NA,NA,"contradictions to exercise",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Rondot & Ziegler (1992)","Activity and acceptability of piribedil in Parkinson's disease: a multicentre study","J. Neurol.","1992","Quasi-experimental study","To determine the efficacy of piribedil as monotherapy in iPS-patients","dopamine_agonist",NA,NA,"Multicentre trial of three months duration; otherwise untreated patients received piribedil, start dosage of 50mg qd, up-titrated to 150-250mg qd","iPS according to unknown clinical criteria"," either tremor-dominance or presence of all cardinal symptoms of iPS"," rest tremor equal to or greater than 1 on Webster scale"," Hoehn and Yahr stages 1 to 3"," no treatment with levodopa before",NA,NA,NA,"pure akinetic parkinsonism"," recent cardiovascular disease"," severe psychological disorder"," psychiatric symptoms"," treatment with monoaminoxidase A or B inhibitors"," intake of neuroleptics or previous treamtent with piribedil",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Saavedra-Escalona et al. 2005","Effect of tens over parkinson‘s disease tremor.","Arch. de Neurocienc.","2005","Quasi-experimental study","To explore the symptomatic effects of tens on iPS-patients' tremor","other",NA,NA,NA,"iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Sahoo et al. 2020","Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinson's disease.","J Neural Transm (Vienna)","2020","Quasi-experimental study","To compare the responsiveness of motor signs to a single fixed dose of trihexphenidyl and levodopa and to compare relative tremor improvement","trihexphenidyl"," levodopa",NA,"Overnight medication withdrawal, consecutively 4mg THP over 48 hours. Then, again, overnight medication withdrawal and administration of 200 and 50mg levodopa and carbidopa, respectively","IPS according to MDS diagnostic criteria"," current or previous medication with trihexphenidyl",NA,NA,NA,NA,NA,NA,"MoCA of less than 26"," contraindications to trihexphenidyl",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Samotus et al. 2017","Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections","PLoS One","2017","Quasi-experimental study","To evaluate the safety and efficacy of kinematically-guided, individualised incobotulinumtoxin A injections for upper limb tremor in iPS-patients","botulinum_toxin",NA,NA,"EMG-guided individualized injections of incobotox into unlateral arm mm. after kinematic tremor assessment with sensors at wrists, elbows and shoulders, injections every 12 weeks, mean dose approx. 150 U","iPS according to UK Brain Bank criteria"," Hoehn and Yahr stage 2 to 3"," predominance of tremor"," stable medication for at least six months"," BoNT-A naive patients",NA,NA,NA,"history of stroke or amyotrophic lateral sclerosis"," contraindications for botox"," pregnancy"," concomitant medication with lithium, valproate, steroids, amoidarone, beta-adrenergic agonists or zonisamide"," history of allergic reactions to botulinum toxin"," pregnancy",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Samotus et al. 2020","Standardized algorithm for muscle selection and dosing of botulinum toxin for Parkinson tremor using kinematic analysis","Ther Adv Neurol Disord","2020","Quasi-experimental study","To investigate rge effects of incobotulinumA injections on tremor of iPS-patients","botulinum_toxin",NA,NA,"EMG-guided individualized injections of incobotox into arm, uni- or bilaterally after kinematic tremor assessment with sensors at wrists, elbows and shoulders. Four injections every 12 weeks, mean dose approximately 150U","iPS according to unknown clinical criteria"," presence of tremor"," stable medication over three months",NA,NA,NA,NA,NA,"history of stroke"," concomitant arm weakness"," allergies"," pregancy",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schlesinger et al. 2009","Parkinson’s Disease Tremor is Diminished with Relaxation Guided Imagery","Mov. Disord.","2009","Quasi-experimental study","To assess the effects of relaxation guided imaginary and relaxing music on tremor","other",NA,NA,"In a two hour session, all participants received a. relaxation guided imagery b. self relaxation period and c. relaxing music. Besides, a baseline period was recorded","iPS according to unknown clinical criteria"," subjects on optimal medical treatment"," rest tremor of at least 3 on item 20 of the UPDRS",NA,NA,NA,NA,NA,"signs of dementia"," presence of dyskinesias",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schlesinger et al. 2009.1","Parkinson’s Disease Tremor is Diminished with Relaxation Guided Imagery","Mov. Disord.","2009","Quasi-experimental study","To assess the effects of relaxation guided imaginary and relaxing music on tremor","other",NA,NA,"In a two hour session, all participants received a. relaxation guided imagery b. self relaxation period and c. relaxing music. Besides, a baseline period was recorded","iPS according to unknown clinical criteria"," subjects on optimal medical treatment"," rest tremor of at least 3 on item 20 of the UPDRS",NA,NA,NA,NA,NA,"signs of dementia"," presence of dyskinesias",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schlesinger et al. 2009.2","Parkinson’s Disease Tremor is Diminished with Relaxation Guided Imagery","Mov. Disord.","2009","Quasi-experimental study","To assess the effects of relaxation guided imaginary and relaxing music on tremor","other",NA,NA,"In a two hour session, all participants received a. relaxation guided imagery b. self relaxation period and c. relaxing music. Besides, a baseline period was recorded","iPS according to unknown clinical criteria"," subjects on optimal medical treatment"," rest tremor of at least 3 on item 20 of the UPDRS",NA,NA,NA,NA,NA,"signs of dementia"," presence of dyskinesias",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Huebsch et al. 2006","Qigong exercise for the symptoms of Parkinson’s disease: A randomized, controlled pilot study","Mov. Disord.","2006","Randomised-controlled trial (RCT)","To investigate the effects of Qigong on iPS-symptoms","physical_therapy",NA,NA,"two courses of weekly 60 minutes sessions of qigong for eights weeks with eight weeks break inbetween versus no intervention","iPS according to UK Brain Bank criteria",NA,NA,NA,NA,NA,NA,NA,"experience with qigong"," changes in medication during previous month before before study"," signs of other central nervous system disease"," dementia with MMSE of less than 24"," clinicalla traceable aphasia",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schneider et al. 1998","Parkinson’s disease improved function with GM1 ganglioside treatment in a randomized placebo-controlled study","Neurology","1998","Randomised-controlled trial (RCT)","To study the effects of GM1-ganglioside injections on motor symptoms of iPS-patients","other",NA,NA,"Allocation to a. GM1-ganglioside or b. placebo group. At entrance, baseline characteristics were evaluated and all subjects received information on how to perform the administration. 1000mg of active substance solved in 50ml saline solution or only saline solution were administered. Afterwards, subjects were instructed to inject themselves 100 mg GM1-ganglioside daily bid versus placebo over 16 weeks","iPS according to unknown clinical criteria"," age between 40 and 80, Hoehn and Yahr stages 1 to 3"," no presence of motor fluctuations",NA,NA,NA,NA,NA,"substance abuse"," severe psychiatric disturbances"," history of stroke"," head injury"," concomitant Guillain-Barre-Syndrome"," women who were not under birth control",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schrag et al. 1999","Reduction of parkinsonian signs in patients with Parkinson’s disease by dopaminergic versus anticholinergic single-dose challenges","Mov. Disord.","1999","Quasi-experimental study","To investigate the effects of single-dose apomorpine or biperiden on tremor, rigidity and bradykinesia in iPS-patients","dopamine_agonist"," anticholinergics",NA,"a. single-dose of subcutanous apomorphine individual dosage determined beforehand, requiring 25 percent UPDRS III reduction or b. 5mg biperiden iv. in off med state","iPS according to UK Brain Bank criteria with tremor",NA,NA,NA,NA,NA,NA,NA,"medical conditions likely to be exacerbated by any of the drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schrag et al. 2002","Ropinirole for the treatment of tremor in early Parkinson's disease","Eur. J. Neurol.","2002","Randomised-controlled trial (RCT)","To analyse the effects of ropinirole on tremor in iPS-patients","ropinirole",NA,NA,"All antiparkinsonian treatments, except selegiline, were discontinued at least 4 weeks prior to study entry. Patients were entered into seven day placebo run-in period to assess compliance. Patients who were at least 80% compliant
were allowed t o continue in the study. Subjects were stratified to a. ropinirole or b. placebo","early stage iPS"," no levodopa premedication six weeks before inclusion"," no dopaminergic medication for two weeks"," stable other antiparkinsonian medication two weeks before inclusion",NA,NA,NA,NA,"Treatment with vasodilators, antiarrhythmics, digoxin, calcium channel blockers, angiotensin-converting enzyme inhibitors, or other antihypertensive agents excluding diuretics"," previous treatment with ropinirole"," history of severe systemic disease, major psychosis, or signs of dementia"," history of severe dizziness or fainting"," diastolic blood pressure of less thsn 110mmHg"," recent history of alcoholism or drug dependence",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schrag et al. 2002.1","Ropinirole for the treatment of tremor in early Parkinson's disease","Eur. J. Neurol.","2002","Randomised-controlled trial (RCT)","To analyse the effects of ropinirole on tremor in iPS-patients","ropinirole"," bromocriptine",NA,"Randomization into two arms with either a. ropinirole and b. bromocriptine. Intake in blinded design td. initial dosages of 0.75 mg and 1.25 mg respectively was titrated upward at weekly intervals according to patients' response up to maximal 24mg ropinirole and 40mg bromocriptine. Levodopa with decarboxylase inhibitor could be used as adjunct medication if therapeutic response insufficient. Efficacy was assessed after 36 months","iPS according to unknown clinical criteria"," age of 30 years or older"," Hoehn and Yahr stages I to III"," no medication with levodopa or dopamine agonists, selegiline, amantanide or anticholinergics for longer than six weeks",NA,NA,NA,NA,"subjects with additional severe systemic or psychiatric diseases"," history of alcohol or drug dependence"," severe dementia",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schrag et al. 2002.2","Ropinirole for the treatment of tremor in early Parkinson's disease","Eur. J. Neurol.","2002","Randomised-controlled trial (RCT)","To analyse the effects of ropinirole on tremor in iPS-patients","ropinirole"," levodopa",NA,"Randomisation to a. ropinirole or b. levodopa. Dosage of study medication were adjusted weekly. Ropinirole was initiated at 0.25mg tid and levodopa therapy at 50mg qd plus placebo twice daily. Maximal dosages were 8mg ropinirole tid  and 400mg levodopa tid. Patients without adequate symptom control despite highest tolerated dose, could be given supplementary levodopa. No other antiparkinsonian therapies were permitted after study initiation.","iPS according to UK Brain Bank criteria"," age between 30 and 80 years"," Hoehn and Yahr stages between 1 and 3)"," necessity of dopaminergic therapy"," Prior treatment with levodopa or dopamine agonists limited to a maximum of six weeks and discontinuation at least two weeks before entry into the study",NA,NA,NA,"Patients suffering from severe dizziness or fainting"," concomitant systemic diseases"," major psychosis"," additional severe dementia"," alcoholism or drug dependence","  contraindication to medication with levodopa"," treatment with monoamine oxidase inhibitor within two weeks before entry with the exception of selegiline"," previous treatment with ropinirole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Sivertsen et al. 1989","Selegiline and levodopa in early or moderately advanced Parkinson’s disease: a double-blind controlled short- and long-term study","Acta Neurol. Scand.","1989","Randomised-controlled trial (RCT)","To investigate the effects of selegiline as an add-on to levodopa in iPS-patients","mao_inhibitor",NA,NA,"a. selegiline 10mg qd. vs. b. placebo for eight weeks. Consecutively, four weeks washout followed by cross-over eight weeks.","iPS according to unknown clinical criteria"," Hoehn and Yahr stage 1 to 3"," stable dosage of levodopa before entering the study",NA,NA,NA,NA,NA,"marked dementia"," concomitant confusion or psychosis"," history of cardiovascular disease"," medication with dopamine agonists",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Spieker et al. 1995","Tremorlytic activity of budipine: A quantitative study with long-term tremor recordings","Clin. Neuropharmacol.","1995","Quasi-experimental study","To investigate the long-term effects of budipine as an add-on in tremor-dominant iPS","budipine",NA,NA,"budipine as an add-on to regular dopaminergic therapy individualized dose, mean 58 mg (range 80,80), 10 surface EMG recording at baseline and after 3-5 months","iPS accordint to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"concomitant anticholinergic medication",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Spieker et al. 1999","Tremorlytic activity of budipine in Parkinson’s disease","Clin. Neuropharmacol.","1999","Randomised-controlled trial (RCT)","To investigate the effects of budipine as an add-on for tremor control in iPS","budipine",NA,NA,"All subjects were treated with either a. bromocriptine 60 mg qd or b. placebo for four months, whith the full dose being reached after six weeks","iPS according to unknown clinical criteria"," constant dosages of levodopa and bromocriptine before inclusion"," LEDD between 200 and 1000mg qd prior to inclusion",NA,NA,NA,NA,NA,"presence of motor fluctuations"," prostate hyperplasia"," concomitant glaucoma"," other anticholinergic medication",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Su et al. 2004","A multi-center, randomized, vitamin E controlled and opening clinical trial of selegiline in patients with Parkinson's disease.","Chinese J. Neurol.","2004","Randomised-controlled trial (RCT)","To investigate the clinical efficacy and safety of selegiline as adjunctive treatment of iPS-patients","selegiline",NA,NA,"Patients were randomly assigned to a. oral administration of 5mg selegiline qd and vitamin E 100mg qd both of which were increased at second week to 10mg qd, and the vitamin 100 mg bid or b. administration of vitamin E 100mg qd and 200mg qd at second week. The other medication remianed unaltered","iPS according to UK Brain Bank criteria"," age between 30 and 80 years"," insufficient symptom control after former antiparkinsonian treatment"," Hoehn and Yahr stages I to III","",NA,NA,NA,"Exclusion of severe heart, lung, liver or kidney disease"," concomitant treatment with serotonin reuptake inhibitors"," medical history of recreational drug or alcohol abuse"," clinical signs of dementia"," concomitant psychosis or other central nervous system diseases","  pregnancy and breastfeeding 
women","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Takahashi et al. 2008","Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching","J Int Med Res","2008","Quasi-experimental study","To investigate the efficacy and safety of switiching from ergot dopamine agonists to pramipexole","pramipexole",NA,NA,"Switching from bromocriptine, cabergoline or pergolide to pramipexole either overnight or over a two week period in equivalent dosages; further dosage adjustment of pramipexole if needed up to 4.5mg qd","iPS according to unknown clinical criteria"," Hoehn and Yahr stages 1 to 4",NA,NA,NA,NA,NA,NA,"concomitant allergies"," additional psychiatric symptoms"," severe hypotension"," concomitant severe heart, kidney or liver dieases"," necessity of long travels by car"," working in height, hazardous daily activities"," pregnancy or breast feeding",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Tedeschi et al. 1990","Tremor in Parkinson disease: acute response to oral levodopa","Ital. J. Neurol. Sci.","1990","Randomised-controlled trial (RCT)","To investigate the acute tremorolytic effect of oral levodopa","levodopa",NA,NA,"patients with levodopa and carbidopa treatment discontinued anti-parkinsonian medication three weeks prior to study. Postural and rest tremor measured four hours after last habitual intake of levodopa and 45 minutes after administration of a single dose of levodopa and carbidopa or placebo. Accelerometric measurement of finger tremor on more affected side","iPS according to UK Brain Bank criteria",NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Trosch et al. 1994","Botulinum toxin a injections for the treatment of hand tremors","Mov. Disord.","1994","Quasi-experimental study","To report effects of botulinumtoxin injections on tremor in iPS and essential tremor","botulinum_toxin",NA,NA,"EMG guided individualized botulinumtoxin injections with mean dosage of 107.5U. Muscles were wrist flexors and extensors in almost all patients, additionally other muscles possible. Booster injections after three weeks allowed","iPS according to unknown clinical criteria"," Hoehn and Yahr stage of less than 3"," stable medication for one month",NA,NA,NA,NA,NA,"alcohol abuse"," presence of polyneuropathy"," concomitant cognitive impairment"," motor fluctuations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Van Laar et al. 1998","Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson’s disease","Clin. Neuropharmacol.","1998","Quasi-experimental study","To characterize the dose-effect relation of apomorphine in iPS-patients","dopamine_agonist",NA,NA,"apomorphine infusion with stepwise increase of dosages every 20 minutes, starting at 10ug per kg per hour and maximum 100 ug per kg per hour, then stepwise decrease to baseline","iPS according to unknown clinical criteria"," stable medication for more than one month",NA,NA,NA,NA,NA,NA,"signs of dementia"," concomitant other diseases",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Vorasoot et al. 2020","Effects of handwriting exercise on functional outcome in Parkinson disease: A randomized controlled trial","J Clin Neurosci","2020","Randomised-controlled trial (RCT)","To determine whether handwriting exercise improves writing skills and motor function of iPS-patients","other",NA,NA,"handwriting exercises for four weeks vs. no intervention","iPS according to UK Brain Bank criteria"," age of at least 18 years"," Hoehn and Yahr stage 1 to 3 on medication"," stable medication for six weeks prior to study participation"," no presence of motor fluctuations",NA,NA,NA,"therapy with DBS"," concomitant neurological or musculoskeletal disorders",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Weiner et al. 1989","The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson’s disease","J. Neurol. Neurosurg. Psychiatry","1989","Quasi-experimental study","Evaluate efficacy and safety of PHNO and Naxagolide in iPS-patients","other",NA,NA,"four three-day treatment periods with PHNO in increasing dosages from 0.25 to 1mg with 4 day wash-out periods in between","iPS according to unknown clinical criteria"," Hoehn and Yahr stage 2-3"," levodopa-responsiveness",NA,NA,NA,NA,NA,"intake of anticholinergics, dopamine agonists or amantadine within one week before enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Wilken et al. 2019","Latency of re-emergent tremor in Parkinson's disease is influenced by levodopa","Parkinsonism Relat. Disord.","2019","Quasi-experimental study","Study effects of levodopa on amplitude of re-emergent tremor and on tremor pause duration","levodopa",NA,NA,"Acute levodopa challenge test after 12h to 24h medication withdrawal. Baseline tremor activity at rest and with stretched-out arms measured using an accelerometer. Administration of 250mg levodopa. Measurement repeated every 20min after medication until lowest motor score was registered.","IPS according to MDS diagnostic criteria"," presence of rest and re-emergent tremor"," age > 18 years"," Hoehn and Yahr stages 1 to 3",NA,NA,NA,NA,"other known causes of tremor"," recent exposure to tremorgenic drugs"," coexistence of essential tremor"," anatomic or orthopedic upper limb disorders",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Yoshii et al. 1996","Treatment of Essential and Parkinsonian Tremor with Nipradilol","Intern. Med.","1996","Quasi-experimental study","To investigate the efficacy and safety of nipradilol for treating tremor in 20 patient with essential tremor and 20 patients with iPS","beta_blocker",NA,NA,"Administration of 6mg nipradilol bid for 8 weeks, with no other beta-blockers within two weeks prior to study and during study. IPS medication unchanged during entire study.","iPS according to unknown clinical criteria",NA,NA,NA,NA,NA,NA,NA,"severe cardiovascular disease"," systolic blood pressure <100 mmHg"," bronchial asthma"," chronic pulmonary disease"," inadequately controlled diabetes mellitus"," pregnant women",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Zach et al. 2017","Cognitive Stress Reduces the Effect of Levodopa on Parkinson’s Resting Tremor","CNS Neurosci Ther","2017","Quasi-experimental study","To explore the acute effects of levodopa and cognitive stress on resting tremor in iPS-patients","other",NA,NA,"All subjects received levodopa challenge in off-medication state with single dose of 200 of levodopa and 50mg of benserazide","iPS according to UK Brain Bank criteria"," rest tremor with amplitude greater than 0 at least at one upper extremity",NA,NA,NA,NA,NA,NA,"neurological comorbidities"," entrainment or distractibility of tremor"," allergies against any study medication"," MMSE less than 24"," FAB less than 12","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Zach et al. 2020","Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease.","Neurology","2020","Quasi-experimental study","To explore the effects of supramaximal single dose of levodopa on resting tremor in iPS-patients","levodopa",NA,NA,"After overnight medication withdrawal, administration of single dose dispersible 200mg levodopa and benserazide. Measurement of MDS-UPDRS, accelerometry dorsal on one hand, tremor during rest and during cognitive coactivation","iPS-patient according to UK Brain Bank criteria"," resting tremor that is MDS-UPDRS item 17 greater than 0 at least at one limb",NA,NA,NA,NA,NA,NA,"neurologic comorbidities"," signs of psychogenic tremor"," allergies"," MMSE score less than 25"," FAB score less than 13"," improvement of less than 0,2 after levodopa in akinesia and rigidity MDS-UPDRS subscores",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Zhang et al. 2013","Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson’s disease: A randomized, double-blind, parallel-controlled, multi-centre trial","Int J Neuropsychopharmacol","2013","Randomised-controlled trial (RCT)","To investigate the effects of rasagiline as an add-on to levodopa in Chinese iPS-patients","rasagiline",NA,NA,"Participants reveived either a. 1mg rasagiline qd  or b. placebo over 12 weeks. Assessments at baseline and after this period","IPS according to clinical diagnosis with at least two of the symptoms bradykinesia, tremor, rigidity"," age between 30 and 75"," disease duration of less than 10 years"," presence of motor fluctuations"," Hoehn and Yahr stage less than 5 in OFF medication state"," levodopa dose less than 800mg qd",NA,NA,"medication with selegiline within last 60 days"," medication with fluoxetine or fluvoxamine within last 35 days"," significant cognitive dysfunction"," psychiatric problems"," any severe illness"," allergies"," addictions"," pregnancy"," breast feeding"," glaucoma"," dysphagia"," consciousness disorders",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Zhang et al. 2018","The efficacy of homemade tolcapone in the treatment of patients with parkinson’s disease","Exp Ther Med","2018","Randomised-controlled trial (RCT)","To investigate the effects of homemade tolcapone on motor symptoms of iPS-patients","comt_inhibitor",NA,NA,"26 weeks of 100 mg tolcapone as an add-on to levodopa td","iPS according to unknown clinical criteria"," age between 40 and 70 years"," Hoehn and Yahr stage of less than 5 in the ON condition"," stable medication in previous month",NA,NA,NA,NA,"heart disease"," liver disease"," kindey diease"," atypical Parkinsonism"," allergies to drugs or food"," neoplastic disease"," history of mental illness"," hepatitis B"," pregnancy"," breast feeding women",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Zhao et al. 2015","A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson’s disease","Parkinsonism Relat Disord.","2015","Randomised-controlled trial (RCT)","evaluate effects of droxidopa as add-on on motor symptoms and daily living in iPS-patients","droxidopa",NA,NA,"200 mg droxidopa td vs. placebo for 6 weeks","iPS according to UK Brain Bank criteria"," age 45-75"," Hoehn and Yahr stage greater than 3 in the ON condition",NA,NA,NA,NA,NA,"prior intake of COMT- or MAO-inhibitors"," pregnancy"," other diseases"," Deep Brain Stimulation",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Zhou et al. 2019","DL-3-n-butylphthalide therapy for Parkinson’s disease: A randomized controlled trial","Exp Ther Med","2019","Randomised-controlled trial (RCT)","investigate effects of DL-3-n-butylphthalide on motor symptoms, sleep and quality of life in iPS-patients","other",NA,NA,"NBP 200mg td for 24 weeks as an add-on or monotherapy vs. no treatment","iPS according to UK Brain Bank criteria"," age 40-80"," stable medication for 6 weeks or without prior medication"," relative or friend willing to participate",NA,NA,NA,NA,"gastrointestinal, hepatic, renal, respiratory or cardiac disease"," infections"," alcoholism"," drug addiction"," hypersensitivity to celery"," any factor precluding neuropsychological testing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ziegler M.  & Rondot P. (1999)","Activité du piribédil dans la maladie de Parkinson.","La presse medicale","1999","Quasi-experimental study","To investigate the effects of piribedil on levodopa-naive patients with Parkinson’s disease","piribedil",NA,NA,"Measurement at baseline and after three months by experienced neurologist and severeity scored by means of the Webster scale","iPS-patient according to unknown clinical criteria"," resting tremor present with a score of more than 1 on the Webster scale"," Hoehn and Yahr stages between 1 and 3",NA,NA,NA,NA,NA,"bradykinetic-rigid subtypes"," recent cardiovascular diseases such as myocardial infarction or orthostatic dysfunction"," psychiatric comorbidities"," chronic renal or liver diseases"," treatment with neuroleptics or MAO-inhibitors or medication other than levodopa to treat symptoms before",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ziegler et al. 2003","Efficacy of Piribedil as Early Combination to Levodopa in Patients with Stable Parkinson’s Disease: A 6-Month, Randomized, Placebo-Controlled Study","Mov. Disord.","2003","Randomised-controlled trial (RCT)","To demonstrate therapeutic benefits of piribedil, in comparison to placebo, as early add-on to levodopa.","piribedil",NA,NA,"administration of placebo during 15 days. Random assignment to a. piribedil plus levodopa or b. placebo plus levodopa. Medication was continued for six months. Starting dosage for medication was 50mg qd. , which was increased every two weeks at 50mg steps to 150mg tid. By the fifth week and up to 6 months, subjects received dosage achieved in the titration phase, whereas levodopa was kept stable until fourth month but could be adjusted afterwards if therapeutic efficacy was not maintained.","iPS according to unknown clinical criteria"," disease duration of less than 10 years"," age between 35 and 75 years"," Hoehn and Yahr stage 1 to 3"," previous therapy with dopamine agonists, anticholinergics, and amantadine discontinued for at least one month before screening"," levodopa treatment for more than six months but less than eight years"," residual parkinsonism on a stable dosage of levodopa between 150mg and 800mg qd"," patients under treatment with selegiline could participate as long as they were on stable dosage more than one month before enrolment","Concomitant treatment with anxiolytics, hypnotics, and antidepressants except for MAO-inhibitors, amineptine, medifoxamine, fluoxetine, and fluphenazine with nortriptyline iff therapies remained unchanged throughout the trial"," presence of motor fluctuations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
